Biogen Inc Cmn (BIIB) 238.62 $BIIB
Brexit Broke the Stock Market — But One Sector Remains a “Buy”
Greg Guenthner - Daily Reckoning - Thu Jun 23, 8:55AM CDT
This post Brexit Broke the Stock Market — But One Sector Remains a “Buy” appeared first on Daily Reckoning . We have to do our best to tune out the insanity and hope that the market gives us some direction. Today, Greg...
BIIB: 238.62 (+4.02)
Watch for Biogen Idec to Potentially Rebound After Falling 1.26% Yesterday
Comtex SmarTrend(R) - Tue Jun 21, 12:27PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $234.04 to a high of $238.99. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $236.54 on volume of 769,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 238.62 (+4.02)
Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology
BusinessWire - Tue Jun 21, 10:00AM CDT
Biogen (NASDAQ: BIIB) announced today the appointment of Paul McKenzie, Ph.D., as executive vice president, Pharmaceutical Operations & Technology, effective July 1, 2016. He will report to George A. Scangos, Ph.D., chief executive officer, and will be a member of the Biogen management team. Dr. McKenzie was promoted from his previous position as senior vice president of Global Biologics Manufacturing and Technical Operations.
BIIB: 238.62 (+4.02)
Biogen to Report Second Quarter 2016 Financial Results on July 21, 2016
BusinessWire - Mon Jun 20, 3:01PM CDT
Biogen Inc. (NASDAQ:BIIB) today announced it will report second quarter 2016 financial results on Thursday, July 21, 2016, before the financial markets open.
BIIB: 238.62 (+4.02)
Stock Market News for June 16, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 9:10AM CDT
Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year
AGN: 233.51 (+4.96), BIIB: 238.62 (+4.02), MDT: 85.77 (+1.51), ALXN: 123.57 (+2.16), XOM: 91.80 (+0.63), BMY: 72.64 (+0.33), CVX: 104.44 (+2.15)
Biotechnology Equities Technical Briefing -- PTC Therapeutics, Biogen, Progenics Pharma, and VIVUS
PR Newswire - Tue Jun 14, 6:35AM CDT
On Monday, June 13, 2016, the NASDAQ Composite ended the trading session at 4,848.44, down 0.94%; the Dow Jones Industrial Average edged 0.74% lower, to finish at 17,732.48; and the S&P 500 closed at 2,079.06, down 0.81%. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Biogen Inc. (NASDAQ: BIIB), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and VIVUS Inc. (NASDAQ: VVUS). Learn more about these stocks by accessing their free trade alerts at:
PGNX: 4.78 (+0.12), BIIB: 238.62 (+4.02), VVUS: 1.10 (unch), PTCT: 7.00 (+0.40)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
BIIB: 238.62 (+4.02), BMRN: 83.65 (+1.47), ALXN: 123.57 (+2.16), IBB: 262.10 (+5.54), REGN: 357.14 (+5.22)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 238.62 (+4.02), BMRN: 83.65 (+1.47), SRPT: 17.88 (+0.47), ALXN: 123.57 (+2.16), IBB: 262.10 (+5.54), REGN: 357.14 (+5.22)
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 6.12 (-0.08), BIIB: 238.62 (+4.02), IDRA: 1.53 (+0.05), RTRX: 18.49 (+0.01), ACOR: 26.31 (+1.04)
New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen's Anti-TNF Biosimilars Portfolio
BusinessWire - Thu Jun 09, 6:08AM CDT
Data demonstrating long-term comparable efficacy, safety and immunogenicity of BENEPALI(R) (etanercept) and FLIXABI(R) (infliximab) were presented by Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen (NASDAQ: BIIB), at the Annual European Congress of Rheumatology (EULAR 2016), held 8-11 June in London, UK. Results showed that in patients who were switched from the reference product Enbreli to BENEPALI, there were no treatment-emergent safety or immunogenicity issues, and efficacy was sustained for up to two years.ii Comparable safety, immunogenicity and sustained efficacy were also demonstrated in patients who were switched from Remicadeiii to FLIXABI, compared with those who continued on Remicade.iv BENEPALI and FLIXABI were both approved by the European Commission (EC) earlier this year and are commercialized in Europe by Biogen.
BIIB: 238.62 (+4.02)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 238.62 (+4.02), SRPT: 17.88 (+0.47), ALXN: 123.57 (+2.16), AMGN: 152.27 (+2.46), ABBV: 61.31 (+0.92), REGN: 357.14 (+5.22), CELG: 100.66 (+1.43)
Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 6.12 (-0.08), BIIB: 238.62 (+4.02), IDRA: 1.53 (+0.05), RTRX: 18.49 (+0.01), LGND: 115.11 (+1.28), ACOR: 26.31 (+1.04)
Oil Bears Have Lost Their Bite – It’s Time for Energy Stocks to Soar
Greg Guenthner - Daily Reckoning - Wed Jun 08, 8:29AM CDT
This post Oil Bears Have Lost Their Bite – It’s Time for Energy Stocks to Soar appeared first on Daily Reckoning . Nineteen measly points. That’s all that separates the S&P 500 from topping its all-time closing highs. But not all...
BIIB: 238.62 (+4.02)
Why is Biogen (BIIB) Stock Plunging Today?
Madeleine Johnson - Zacks Investment Research - Tue Jun 07, 3:04PM CDT
On Tuesday, shares of biopharmaceutical company Biogen (BIIB) are plunging, down over 15% in afternoon trading after the company???s Phase 2 study of its treatment for relapsing multiple sclerosis failed to meet its primary and secondary endpoints.
BIIB: 238.62 (+4.02)
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 11.93% Loss
Comtex SmarTrend(R) - Tue Jun 07, 11:47AM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $250.87 to a high of $264.73. Yesterday, the shares fell 11.9%, which took the trading range below the 3-day low of $283.79 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 238.62 (+4.02)
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 11.93%
Comtex SmarTrend(R) - Tue Jun 07, 11:45AM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $250.87 to a high of $264.73. Yesterday, the shares fell 11.9%, which took the trading range below the 3-day low of $283.79 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 238.62 (+4.02)
Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
BusinessWire - Tue Jun 07, 6:30AM CDT
-- Biogen Continues to Analyze Data to Inform Next Step in Clinical Development Program --
BIIB: 238.62 (+4.02)
Kite (KITE) and Biogen's Drugs Included in PRIME Initiative
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 4:55PM CDT
Kite Pharma, Inc. (KITE) announced that its immuno-oncology candidate, KTE-C19, has been granted access to the Priority Medicines (PRIME) regulatory initiative in Europe.
BIIB: 238.62 (+4.02), KITE: 53.11 (+1.97), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)
Brexit Broke the Stock Market — But One Sector Remains a “Buy”
Greg Guenthner - Daily Reckoning - Thu Jun 23, 8:55AM CDT
This post Brexit Broke the Stock Market — But One Sector Remains a “Buy” appeared first on Daily Reckoning . We have to do our best to tune out the insanity and hope that the market gives us some direction. Today, Greg...
BIIB: 238.62 (+4.02)
Watch for Biogen Idec to Potentially Rebound After Falling 1.26% Yesterday
Comtex SmarTrend(R) - Tue Jun 21, 12:27PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $234.04 to a high of $238.99. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $236.54 on volume of 769,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 238.62 (+4.02)
Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology
BusinessWire - Tue Jun 21, 10:00AM CDT
Biogen (NASDAQ: BIIB) announced today the appointment of Paul McKenzie, Ph.D., as executive vice president, Pharmaceutical Operations & Technology, effective July 1, 2016. He will report to George A. Scangos, Ph.D., chief executive officer, and will be a member of the Biogen management team. Dr. McKenzie was promoted from his previous position as senior vice president of Global Biologics Manufacturing and Technical Operations.
BIIB: 238.62 (+4.02)
Biogen to Report Second Quarter 2016 Financial Results on July 21, 2016
BusinessWire - Mon Jun 20, 3:01PM CDT
Biogen Inc. (NASDAQ:BIIB) today announced it will report second quarter 2016 financial results on Thursday, July 21, 2016, before the financial markets open.
BIIB: 238.62 (+4.02)
Stock Market News for June 16, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 9:10AM CDT
Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year
AGN: 233.51 (+4.96), BIIB: 238.62 (+4.02), MDT: 85.77 (+1.51), ALXN: 123.57 (+2.16), XOM: 91.80 (+0.63), BMY: 72.64 (+0.33), CVX: 104.44 (+2.15)
Biotechnology Equities Technical Briefing -- PTC Therapeutics, Biogen, Progenics Pharma, and VIVUS
PR Newswire - Tue Jun 14, 6:35AM CDT
On Monday, June 13, 2016, the NASDAQ Composite ended the trading session at 4,848.44, down 0.94%; the Dow Jones Industrial Average edged 0.74% lower, to finish at 17,732.48; and the S&P 500 closed at 2,079.06, down 0.81%. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Biogen Inc. (NASDAQ: BIIB), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and VIVUS Inc. (NASDAQ: VVUS). Learn more about these stocks by accessing their free trade alerts at:
PGNX: 4.78 (+0.12), BIIB: 238.62 (+4.02), VVUS: 1.10 (unch), PTCT: 7.00 (+0.40)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
BIIB: 238.62 (+4.02), BMRN: 83.65 (+1.47), ALXN: 123.57 (+2.16), IBB: 262.10 (+5.54), REGN: 357.14 (+5.22)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 238.62 (+4.02), BMRN: 83.65 (+1.47), SRPT: 17.88 (+0.47), ALXN: 123.57 (+2.16), IBB: 262.10 (+5.54), REGN: 357.14 (+5.22)
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 6.12 (-0.08), BIIB: 238.62 (+4.02), IDRA: 1.53 (+0.05), RTRX: 18.49 (+0.01), ACOR: 26.31 (+1.04)
New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen's Anti-TNF Biosimilars Portfolio
BusinessWire - Thu Jun 09, 6:08AM CDT
Data demonstrating long-term comparable efficacy, safety and immunogenicity of BENEPALI(R) (etanercept) and FLIXABI(R) (infliximab) were presented by Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen (NASDAQ: BIIB), at the Annual European Congress of Rheumatology (EULAR 2016), held 8-11 June in London, UK. Results showed that in patients who were switched from the reference product Enbreli to BENEPALI, there were no treatment-emergent safety or immunogenicity issues, and efficacy was sustained for up to two years.ii Comparable safety, immunogenicity and sustained efficacy were also demonstrated in patients who were switched from Remicadeiii to FLIXABI, compared with those who continued on Remicade.iv BENEPALI and FLIXABI were both approved by the European Commission (EC) earlier this year and are commercialized in Europe by Biogen.
BIIB: 238.62 (+4.02)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 238.62 (+4.02), SRPT: 17.88 (+0.47), ALXN: 123.57 (+2.16), AMGN: 152.27 (+2.46), ABBV: 61.31 (+0.92), REGN: 357.14 (+5.22), CELG: 100.66 (+1.43)
Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 6.12 (-0.08), BIIB: 238.62 (+4.02), IDRA: 1.53 (+0.05), RTRX: 18.49 (+0.01), LGND: 115.11 (+1.28), ACOR: 26.31 (+1.04)
Oil Bears Have Lost Their Bite – It’s Time for Energy Stocks to Soar
Greg Guenthner - Daily Reckoning - Wed Jun 08, 8:29AM CDT
This post Oil Bears Have Lost Their Bite – It’s Time for Energy Stocks to Soar appeared first on Daily Reckoning . Nineteen measly points. That’s all that separates the S&P 500 from topping its all-time closing highs. But not all...
BIIB: 238.62 (+4.02)
Why is Biogen (BIIB) Stock Plunging Today?
Madeleine Johnson - Zacks Investment Research - Tue Jun 07, 3:04PM CDT
On Tuesday, shares of biopharmaceutical company Biogen (BIIB) are plunging, down over 15% in afternoon trading after the company???s Phase 2 study of its treatment for relapsing multiple sclerosis failed to meet its primary and secondary endpoints.
BIIB: 238.62 (+4.02)
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 11.93% Loss
Comtex SmarTrend(R) - Tue Jun 07, 11:47AM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $250.87 to a high of $264.73. Yesterday, the shares fell 11.9%, which took the trading range below the 3-day low of $283.79 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 238.62 (+4.02)
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 11.93%
Comtex SmarTrend(R) - Tue Jun 07, 11:45AM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $250.87 to a high of $264.73. Yesterday, the shares fell 11.9%, which took the trading range below the 3-day low of $283.79 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 238.62 (+4.02)
Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
BusinessWire - Tue Jun 07, 6:30AM CDT
-- Biogen Continues to Analyze Data to Inform Next Step in Clinical Development Program --
BIIB: 238.62 (+4.02)
Kite (KITE) and Biogen's Drugs Included in PRIME Initiative
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 4:55PM CDT
Kite Pharma, Inc. (KITE) announced that its immuno-oncology candidate, KTE-C19, has been granted access to the Priority Medicines (PRIME) regulatory initiative in Europe.
BIIB: 238.62 (+4.02), KITE: 53.11 (+1.97), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)
